MXPA01011923A - Composiciones y metodos para tratar alteraciones en la proliferacion celular. - Google Patents

Composiciones y metodos para tratar alteraciones en la proliferacion celular.

Info

Publication number
MXPA01011923A
MXPA01011923A MXPA01011923A MXPA01011923A MXPA01011923A MX PA01011923 A MXPA01011923 A MX PA01011923A MX PA01011923 A MXPA01011923 A MX PA01011923A MX PA01011923 A MXPA01011923 A MX PA01011923A MX PA01011923 A MXPA01011923 A MX PA01011923A
Authority
MX
Mexico
Prior art keywords
compositions
methods
cell proliferation
proliferation disorders
treating cell
Prior art date
Application number
MXPA01011923A
Other languages
English (en)
Spanish (es)
Inventor
Jacques Banchereau
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of MXPA01011923A publication Critical patent/MXPA01011923A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MXPA01011923A 1999-05-17 2000-03-27 Composiciones y metodos para tratar alteraciones en la proliferacion celular. MXPA01011923A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99401191A EP1053751A1 (en) 1999-05-17 1999-05-17 Compositions and methods for treating cell proliferation disorders
PCT/US2000/008081 WO2000069463A1 (en) 1999-05-17 2000-03-27 Compositions and methods for treating cell proliferation disorders

Publications (1)

Publication Number Publication Date
MXPA01011923A true MXPA01011923A (es) 2003-10-15

Family

ID=8241974

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA01011923A MXPA01011923A (es) 1999-05-17 2000-03-27 Composiciones y metodos para tratar alteraciones en la proliferacion celular.

Country Status (6)

Country Link
EP (2) EP1053751A1 (cg-RX-API-DMAC7.html)
JP (1) JP2004500325A (cg-RX-API-DMAC7.html)
AU (1) AU4033900A (cg-RX-API-DMAC7.html)
CA (1) CA2373938A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA01011923A (cg-RX-API-DMAC7.html)
WO (1) WO2000069463A1 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2350687T3 (es) * 2002-07-03 2011-01-26 Ono Pharmaceutical Co., Ltd. Composiciones de inmunopotenciación.
EP3594228A1 (en) 2003-07-08 2020-01-15 Genentech, Inc. Il-17a/f heterologous polypedtides and therapeutic uses thereof
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
GB0425569D0 (en) * 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
CN101374864A (zh) * 2006-01-31 2009-02-25 诺瓦提斯公司 用于靶向癌症的il-17拮抗性抗体
GB0612928D0 (en) 2006-06-29 2006-08-09 Ucb Sa Biological products
GB0620729D0 (en) 2006-10-18 2006-11-29 Ucb Sa Biological products
GB0807413D0 (en) 2008-04-23 2008-05-28 Ucb Pharma Sa Biological products
US20100233270A1 (en) 2009-01-08 2010-09-16 Northwestern University Delivery of Oligonucleotide-Functionalized Nanoparticles
WO2011141823A2 (en) * 2010-05-14 2011-11-17 Orega Biotech Methods of treating and/or preventing cell proliferation disorders with il-17 antagonists
MY162790A (en) 2011-01-14 2017-07-14 Ucb Pharma Sa Antibody molecules which bind il-17a and il-17f
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
AU2015269412B2 (en) 2014-06-04 2020-03-12 Exicure Operating Company Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
AU2017261360A1 (en) 2016-05-06 2018-11-29 Exicure Operating Company Liposomal Spherical Nucleic Acid (SNA) constructs presenting Antisense Oligonucleotides (ASO) for specific knockdown of interleukin 17 receptor MRNA
US11696954B2 (en) 2017-04-28 2023-07-11 Exicure Operating Company Synthesis of spherical nucleic acids using lipophilic moieties
EP4087858A1 (en) * 2020-01-10 2022-11-16 Carogen Corporation Compositions and methods of use of oncolytic virus like vesicles

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69634726T2 (de) * 1995-07-19 2006-05-04 Genetics Institute, LLC, Cambridge Menschliche ctla-8 und verwendung von ctla-8 ähnlichen proteinen
WO1999014240A1 (en) * 1997-09-17 1999-03-25 Human Genome Sciences, Inc. Interleukin-17 receptor-like protein
DE29820466U1 (de) * 1998-11-16 1999-04-08 Reutter, Werner, Prof. Dr.med., 14195 Berlin Rekombinante Glycoproteine und sie enthaltende Arzneimittel

Also Published As

Publication number Publication date
EP1251872A1 (en) 2002-10-30
CA2373938A1 (en) 2000-11-23
AU4033900A (en) 2000-12-05
EP1053751A1 (en) 2000-11-22
JP2004500325A (ja) 2004-01-08
WO2000069463A1 (en) 2000-11-23

Similar Documents

Publication Publication Date Title
HUP0201436A3 (en) Methods and compositions for treating solid tumors
AU8003800A (en) Methods and compositions for treating neurobehavioral disorders
IL208191A0 (en) Compositions and methods for treating rage-associated disorders
PL330496A1 (en) Methods of and compositions for treating and preventing tumours, disorders associated with tumours as well as cachexy
MXPA01011923A (es) Composiciones y metodos para tratar alteraciones en la proliferacion celular.
AU3877900A (en) Compositions and methods for preventing and treating sexual dysfunctions
AU5294100A (en) Method and compositions for treating the inflammatory response
AU7360000A (en) Methods and compositions for preventing and treating prostate disorders
EP1572118A4 (en) METHOD AND COMPOSITIONS FOR TREATING CANCER WITH 15986, 2188, 20743, 9148, 9151, 9791, 44252, 14184, 42461, 8204, 7970, 25552, 21657, 26492, 2411, 15088, 1905, 28899, 63380, 33935, 10480, 12686, 25501, 17694, 15701, 53062, 49908, 21612, 38949, 6216, 46863, 9235, 2201, 6985, 9883, 12238, 18057, 216
HUP0002101A3 (en) Fluoroether compositions, process for producing them and methods for inhibiting their degradation
GB9821217D0 (en) Treatment for substrates
AU4314199A (en) Compounds, compositions and methods for treating erectile dysfunction
MXPA02003232A (es) Composiciones y metodos para alternar la expresion de genes.
AU1359801A (en) Methods and compositions for treating reward deficiency syndrome
PL353214A1 (en) Substituted 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-ones and their use as lipase inhibitors
ZA200203435B (en) Method and compositions for treating pulmonary diseases.
GB2339576B (en) Biomass treatment
GB9912851D0 (en) Treating cells
IL145220A0 (en) Stabilized composition based on pyridinyl-sulfinyl-benzimidazoles and process
AU6006800A (en) Treating cells
AUPQ872800A0 (en) Compositions and methods for treating cardiovascular disorders
AU5169200A (en) Methods and compositions for treating breakthrough pain
AU5097099A (en) Methods and compositions for cancer treatment
AU7604100A (en) Composition and method for treating burns
EP1425020A4 (en) METHOD AND COMPOSITIONS FOR TREATING APOPTOSIS-RELATED DISEASES

Legal Events

Date Code Title Description
FA Abandonment or withdrawal